Auris Medical Holding AG (NASDAQ:EARS) was the target of a significant drop in short interest in the month of September. As of September 15th, there was short interest totalling 817,664 shares, a drop of 28.7% from the August 31st total of 1,146,344 shares. Approximately 5.8% of the shares of the stock are short sold. Based on an average daily volume of 753,396 shares, the days-to-cover ratio is presently 1.1 days.
Institutional investors have recently made changes to their positions in the company. Bellevue Group AG purchased a new position in shares of Auris Medical Holding AG during the first quarter worth approximately $7,897,000. Advisor Group Inc. purchased a new position in shares of Auris Medical Holding AG during the second quarter worth approximately $277,000. Finally, TFS Capital LLC increased its position in shares of Auris Medical Holding AG by 17.7% in the second quarter. TFS Capital LLC now owns 38,230 shares of the company’s stock worth $160,000 after buying an additional 5,762 shares during the last quarter. Institutional investors own 30.95% of the company’s stock.
Auris Medical Holding AG (NASDAQ:EARS) opened at 1.73 on Friday. The stock’s market capitalization is $59.39 million. The firm’s 50-day moving average is $2.09 and its 200-day moving average is $3.39. Auris Medical Holding AG has a 52 week low of $1.55 and a 52 week high of $7.96.
EARS has been the topic of several research analyst reports. Zacks Investment Research upgraded shares of Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research report on Tuesday, July 12th. Leerink Swann restated a “buy” rating and set a $12.00 price target on shares of Auris Medical Holding AG in a research report on Wednesday, June 15th. Jefferies Group restated a “buy” rating on shares of Auris Medical Holding AG in a research report on Friday, June 10th. Needham & Company LLC boosted their price target on shares of Auris Medical Holding AG from $5.00 to $11.00 and gave the stock a “buy” rating in a research report on Friday, August 19th. Finally, JMP Securities lowered shares of Auris Medical Holding AG from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 18th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Auris Medical Holding AG has a consensus rating of “Buy” and a consensus target price of $8.88.
About Auris Medical Holding AG
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.
Receive News & Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related companies with MarketBeat.com's FREE daily email newsletter.